Is Syndax (SNDX) Using ESOP Shares and New Drugs to Quietly Redefine Its Investment Story? [Yahoo! Finance]
Syndax Pharmaceuticals, Inc. (SNDX)
Last syndax pharmaceuticals, inc. earnings: 3/3 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.syndax.com
Company Research
Source: Yahoo! Finance
and reported Q4 2025 results showing strong revenue growth but a wider-than-expected loss. The combination of robust uptake of Revuforj and Niktimvo, three FDA approvals within a year, and a solid cash position highlights Syndax's growing commercial scale and funding flexibility. We'll now examine how Syndax's accelerating product revenues and recent financing flexibility reshape the company's broader investment narrative for investors. Find 46 companies with promising cash flow potential yet trading below their fair value Syndax Pharmaceuticals Investment Narrative Recap To own Syndax, you need to believe that Revuforj and Niktimvo can grow into durable franchises while the company steadily narrows its losses. The key near term catalyst is continued revenue momentum and potential label expansion for Revuforj, while the main risk is ongoing reliance on just two products amid sustained net losses. The new US$77.73 million ESOP shelf and a wider Q4 loss do not materially chang
Show less
Read more
Impact Snapshot
Event Time:
SNDX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNDX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNDX alerts
High impacting Syndax Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
SNDX
News
- Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
- Syndax Pharmaceuticals (SNDX) had its price target raised by Citigroup Inc. from $51.00 to $57.00. They now have a "buy" rating on the stock.MarketBeat
- Syndax Pharmaceuticals Inc. (SNDX) on a Strong Footing amid Robust Demand for Key Flagship Drugs [Yahoo! Finance]Yahoo! Finance
- Syndax Pharmaceuticals Inc (SNDX) Q4 2025 Earnings Call Highlights: Robust Revenue Growth and ... [Yahoo! Finance]Yahoo! Finance
- Syndax Pharmaceuticals (SNDX) was given a new $45.00 price target by Stifel Nicolaus.MarketBeat
SNDX
Earnings
- 2/26/26 - Miss
SNDX
Sec Filings
- 2/26/26 - Form S-8
- 2/26/26 - Form 10-K
- 2/26/26 - Form 8-K
- SNDX's page on the SEC website